Company Overview and News

Above-market earnings growth expected for glove sector

7h theedgemarkets
Glove sector Upgrade to neutral: The sector has further rerated in 2018 year to date (YTD) and at a weighted average 12-months (12M) forward price earnings (PER) of 33 times, it is a new high. That said, we think current valuation could stay in the second half of 2018 (2H18) supported by the sector’s above-market earnings growth prospects. We now benchmark glove stocks against the sector’s 12M forward PER on our unchanged 2019 earnings per share (EPS )forecasts.
TGLVY 7113 TPGVF 7153 5168 HRGHY

Maybank IB upgrades Malaysian glove sector to ‘neutral’

The research house, which upgraded its recommendation on the glove sector to “neutral”, also said that the sector’s valuation has hit a new all-time high.
TGLVY 7113 TPGVF 7153 5168 HRGHY

KLCI falls 0.37% in line with loss at regional markets

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI fell 0.37% in early trade this morning in line with the retreat at most regional markets, on heightened worries over the trade spat between the world’s two largest economies.
HLFBF KLKBY 2445 PBLOF 4065 1082 5681 BATS 4162 1295 7153 3719

Rubber glove counters rise on weakening ringgit

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): Export-oriented glove maker counters traded higher today as investors take a bet that the weakening ringgit against the greenback will boost their earnings.

KLCI pares loss, down 0.25% as select blue chips drag

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): The FBM KLCI pared some of its loss at the midday break today and was down 0.25%, dragged by select blue chips.
PBLOF 7113 5253 BATS TPGVF 4162 AMMHF 1295 7153 2089 7077 5226 1201 PNAGF SPMXF UPBMF 7087 6033 TGLVY PNADF 4588 1015 SPMXY 5819 BSMAF 3719 1818

KLCI remains under pressure as select blue chips weigh

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI remained under pressure at mid-morning today, dragged by select index-linked blue chips.
HLFBF 7251 UPBMF 1082 7113 5032 TPGVF BATS 4162 7153 5168 2089 9334 TGLVY 5139 0047 5347 3026 0104 0900 6645 TNABY TNABF HRGHY

KLCI reverses loss, rises 0.54%

2018-06-11 theedgemarkets
KUALA LUMPUR (June 11): The FBM KLCI reversed its earlier losses and rose 0.54% at the midday break, tracking gains at most regional markets.
7251 7113 5681 TPGVF 7153 7077 9334 6033 2186 CIMDF 0166 TGLVY 1023 0047 PNADF 3026 2836 PNAGF

Top Glove share price hits record high in early trade

PETALING JAYA: Top Glove Corp Bhd ’s share price hit a record high of RM10.80 in early trade yesterday as the world’s largest glove manufacturer continued its year-long uptrend on the back of strong rubber glove demand.

Supermax surges as analysts turn upbeat

Investment option: Supermax’s undervaluation gives more buying opportunities for investors seeking to benefit from the rubber glove industry’s performance.
TGLVY 7113 TPGVF 7153 5168 HRGHY

Halyard Health upgraded to overweight from sector weight at KeyBanc Capital

2018-04-06 marketwatch
Of the 28 analysts covering Stryker in February 2018, 11 of them have given the stock a “strong buy” rating, and eight have given it a “buy.”

Kossan unit buys land for RM82.42mil

Both parcels of land will be used for Kossan group’s integrated glove manufacturing expansion, the Bursa Malaysia filing said. The acquisition was funded by internally generated funds.
7153 BSMAF 1818

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...